Myles Minter

Stock Analyst at William Blair

(2.60)
# 2,136
Out of 5,237 analysts
25
Total ratings
57.89%
Success rate
14.61%
Average return

Stocks Rated by Myles Minter

Korro Bio
Feb 17, 2026
Upgrades: Outperform
Price Target: n/a
Current: $11.46
Upside: -
Neumora Therapeutics
Feb 17, 2026
Upgrades: Outperform
Price Target: n/a
Current: $1.87
Upside: -
Biohaven
Nov 5, 2025
Downgrades: Market Perform
Price Target: n/a
Current: $9.08
Upside: -
Alector
Oct 22, 2025
Downgrades: Market Perform
Price Target: n/a
Current: $2.05
Upside: -
Dianthus Therapeutics
Jul 2, 2025
Initiates: Outperform
Price Target: n/a
Current: $87.12
Upside: -
Immunic
Mar 25, 2025
Initiates: Outperform
Price Target: n/a
Current: $12.00
Upside: -
Camp4 Therapeutics
Nov 5, 2024
Initiates: Outperform
Price Target: n/a
Current: $4.40
Upside: -
argenx SE
Nov 1, 2024
Upgrades: Outperform
Price Target: n/a
Current: $813.28
Upside: -
Arcturus Therapeutics Holdings
Jul 24, 2023
Initiates: Outperform
Price Target: $71
Current: $8.64
Upside: +722.24%
Moderna
Jul 24, 2023
Initiates: Market Perform
Price Target: n/a
Current: $52.88
Upside: -
Initiates: Outperform
Price Target: n/a
Current: $435.17
Upside: -
Downgrades: Market Perform
Price Target: n/a
Current: $331.81
Upside: -
Upgrades: Outperform
Price Target: n/a
Current: $4.09
Upside: -
Initiates: Outperform
Price Target: n/a
Current: $284.84
Upside: -
Upgrades: Outperform
Price Target: n/a
Current: $75.38
Upside: -
Initiates: Outperform
Price Target: $116
Current: $150.59
Upside: -22.97%